Cargando…
Effects of β-blockers therapy on the 28-day and 3-year survival rates of end-stage renal disease patients with cardiovascular disease: a retrospective cohort study
BACKGROUND: β-blockers have been used in the treatment of end-stage renal disease (ESRD) patients and cardiovascular disease (CVD) patients, separately. However, the effects of β-blockers on ESRD patients with CVD have not been fully investigated. This study sought to investigate the effects of β-bl...
Autores principales: | Wang, Yong, Wu, Zheqian, Lu, Shijie, Yin, Lili, Chen, Yuandong, Qiu, Canyi, Ng, Pauline Yeung, Durak, Koray, Deana, Cristian, Ding, Fei, Zhang, Zhiyan, Dai, Lihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761132/ https://www.ncbi.nlm.nih.gov/pubmed/36544684 http://dx.doi.org/10.21037/atm-22-5317 |
Ejemplares similares
-
Downregulation of tripartite motif protein 11 attenuates cardiomyocyte apoptosis after ischemia/reperfusion injury via DUSP1‐JNK1/2
por: He, Fang, et al.
Publicado: (2021) -
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease
por: Zvizdic, Faris, et al.
Publicado: (2019) -
Beta-blockers and physical frailty in patients with end-stage liver disease
por: Kuo, Selena Z, et al.
Publicado: (2018) -
Assessment of 28-Day In-Hospital Mortality in Mechanically Ventilated Patients With Coronavirus Disease 2019: An International Cohort Study
por: Li Bassi, Gianluigi, et al.
Publicado: (2021) -
The effects of Alzheimer's and Parkinson's disease on 28-day mortality of COVID-19
por: Fathi, M., et al.
Publicado: (2022)